Milestones

Dates retain their source precision. Elapsed windows await verification; they never become completed events automatically. Completed shows selected milestones already recorded in the evidence during the past 90 days, not a complete event archive or evidence of approval or clinical benefit. These status labels follow today’s date without advancing a research check.

Milestones

Scheduled events17

Hair-follicle secretome (aHFS) comparison at ISHRS; biochemical differences and small post-laser recovery findings are not proof of improved hair regrowth.

AD109 CHEST postmenopausal, hypoxic-burden/blood-pressure and per-protocol patient-reported analyses; Phoenix program times

Miv-cel full stiff-person-syndrome results at MS Toronto.

SCD-PED SAVE historical-cohort comparison, 10 a.m.–noon Mountain; no result inferred.

PYC-003 ADPKD early safety/PK and target engagement, TH-OR060, 5:20–5:30 p.m. Denver program time; not proven kidney preservation.

INTerpath-001 detailed phase 3 melanoma recurrence-prevention results, 16:30 CEST.

Galleri real-world diagnostic workups, abstract 1164P, 12:00–12:45 local program time.

PATHFINDER2 workup efficiency/safety, abstract 1151, 14:45–16:15 session window local program time.

EMA bacteriophage-therapy evidence/regulatory workshop, 09:00–18:00 CET; online participation, not approval.

Transform-HTN lorundrostat long-term extension data at AHA.

STEP Young full pediatric BMI and safety results at ObesityWeek.

Detailed RADIANT remlifanserin Alzheimer-psychosis findings after the Phase 2 primary-endpoint miss.

BHV-1530 Phase 1 update in Barcelona at 10:00 as stated by the sponsor; full combination-cohort efficacy and safety remain to be assessed.

Ibogaine early-trial RFI comments close; not an efficacy readout.

Giredestrant advanced ESR1-mutated breast-cancer application; target is not guaranteed approval.

Otarmeni confirmatory protocol due; this is not a clinical readout.

mFlusiva postmarketing safety-study protocol due; not a public efficacy readout.

2026 forecast windows66

NCT07822607 start; no public-result date inferred.

SCARFREE-001 start; actual initiation unverified.

TNP-2092 direct-joint infection study start.

NCT04742777 primary/final completion; no public-result date inferred.

ENHANCE-3 ensifentrine COPD estimated start.

NCT07861100 start; no public-result date inferred.

MariTide home-autoinjector trial estimated start

PF-08656795 multiple-dose Phase 1 estimated start

BMS-986553 in-vivo CD19 CAR-T estimated study start.

FXS5626 vitiligo Phase 2/3 start.

TST002 comparative Phase 2 study start; bone-density outcomes do not establish fracture prevention.

SYLKE randomized surgical-dressing trial estimated start; not yet recruiting.

SUNRISE-1 and SUNRISE-2 estimated starts; supersedes October 15/16 plans, no first dosing verified

SUPRA-COPD urolithin A estimated start.

SOARA ovarian blood-screening safety/diagnostic-burden study estimated start.

NCT07853716 start; no public-result date inferred.

Postoperative suzetrigine NCT07856654 study start.

NCT07854782 start; no public-result date inferred.

Kylo-0603 MASLD Phase 2a estimated start

CHF5993 adolescent asthma Phase 3 start.

Recombinant zoster vaccine cardiovascular-outcomes estimated start.

Belotero Intense U.S. commercial availability; approval was earlier.

NCT07850752 start; no public-result date inferred.

NCT06568367 primary/final completion; no public-result date inferred.

NCT07675109 primary completion; no public-result date inferred.

Facial macrofat cohort primary completion; retrospective registration and unfinished protocol fields require follow-up.

Forazapadin FSHD estimated start.

Separate Phase 2 PP405 study in women expected to initiate; actual start not verified.

Abaloparatide added to denosumab final completion; primary already completed September 18, no results.

ALZ-101 phase 2 enrollment; operational preparation is not first dosing.

RZL-012 China filing.

Suzetrigine/VX-993 neuropathy enrollment completion; results are undated.

Utebzi oral antibiotic U.S. availability; launch unverified.

CagriSema FDA decision expected.

SRK-439 Phase 1 topline.

EB613 oral osteoporosis treatment Phase 3 initiation.

VDPHL01 male confirmatory and 12-month data.

Further povorcitinib Phase 3 vitiligo data.

VIASKIN Peanut toddler filing, dependent on supplementary safety-study success.

AP-SA02 phage adjunct Phase 3 initiation; actual start unverified.

ABS201 early hair-growth proof-of-concept; existing blinded safety/PK report does not demonstrate efficacy.

Atacicept supplemental BLA after final ORIGIN 3 kidney-function results; full approval not established.

COMP360 filing completion and HLP003/VLS-01 readouts.

Resmetirom/ervogastat interaction-study start.

DT120 pre-NDA meeting after September 14 Panorama topline; not approval.

Lanifibranor NATiV3 72-week topline; extension follow-up has a separate registry completion estimate.

ORKA-001 EVERLAST-B week-16 psoriasis results.

Prula-cel pivotal lupus-nephritis study start-up; this does not confirm recruitment or first dosing.

Zenkuda three-indication biologics application; a planned filing is not FDA approval.

EloraTZP co-formulated AMPLIFY phase 3 initiation.

Miv-cel rolling stiff-person-syndrome BLA completion.

NVD003 pediatric congenital-tibial-nonunion primary completion; April registry snapshot, no results.

TG-C companion ACTiVION-I topline after the other pivotal trial failed.

HEART-3 VERVE-102 phase 2 start.

DR10624 triglyceride/diabetic-kidney-disease phase 2 start.

KOMET oral-ketamine phase 3 start.

AURORA now has a recruiting registry and activated sites; the sponsor says screening begins this month. Actual first dosing remains unverified.

DECLARATION VYD2311 safety and neutralizing titers; clinical efficacy remains blinded.

Orzeyful availability, pending DEA scheduling; actual launch not verified.

SGT-610 phase 3 Gorlin syndrome topline after the last patient visit; results remain blinded.